SAN DIEGO (BUSINESS WIRE) Apros Therapeutics, Inc., a clinical stage biotechnology company focused on tissue-targeted Toll-Like Receptor 7 (TLR7) agonists for the treatment of advanced cancers and infectious diseases, today announced that they will present interim pharmacokinetic and pharmacodynamic Phase 1 clinic.